ReviewAmerican heart journal plus : cardiology research and practice2025
Diagnosis, clinical management, and emerging strategies for coronary artery disease in patients with cancer.
Review in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coronary artery disease and cancer: Shared risk factors, pathogenesis, and treatment effects.American heart journal plus : cardiology research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intersection of cancer and coronary artery disease (CAD) presents complex clinical challenges requiring a multidisciplinary approach. Building on the first part of this review, which addressed epidemiology, shared risk factors, and pathophysiological mechanisms, this second part focuses on the diagnosis, screening, and management of CAD in patients with cancer, as well as management of cancer in CAD patients. Early identification of CAD remains challenging due to overlapping symptoms; thus, cardiovascular imaging modalities such as echocardiography, coronary computed tomography angiography, and cardiac magnetic resonance imaging, alongside cardiac biomarkers, are essential for accurate detection and risk stratification. Screening strategies emphasize baseline cardiovascular risk evaluation and long-term surveillance, particularly for cancer survivors exposed to cardiotoxic therapies. Management of CAD in this population requires individualized pharmacologic and interventional strategies, balancing thrombotic, bleeding, and oncologic risks. The use of percutaneous coronary intervention and coronary artery bypass grafting (CABG) must be tailored to patient-specific cancer prognosis and cardiovascular status. Moreover, several cancer therapies, including ERBB-2-targeted agents, angiogenesis inhibitors, and immune checkpoint inhibitors, are associated with cardiovascular toxicities, necessitating vigilant monitoring and timely interventions. Emerging fields such as anti-inflammatory therapy, clonal hematopoiesis of indeterminate potential integration, and artificial intelligence-based risk prediction offer promising strategies for improving outcomes. This second part of the review highlights the importance of a multidisciplinary cardio-oncology approach to optimize care for patients facing the dual burden of cancer and CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.